Tyrosinemia type II
<templatestyles src="Module:Hatnote/styles.css"></templatestyles>
| Tyrosinemia type II | |
|---|---|
|
|
| Classification and external resources | |
| Specialty | Lua error in Module:Wikidata at line 446: attempt to index field 'wikibase' (a nil value). |
| ICD-10 | E70.2 |
| ICD-9-CM | 270.2 |
| OMIM | 276600 |
| DiseasesDB | 13486 |
| eMedicine | ped/2339 |
| Patient UK | Tyrosinemia type II |
| MeSH | D020176 |
Tyrosinemia type II (Oculocutaneous tyrosinemia,[1] Richner-Hanhart syndrome[1]:543) is an autosomal recessive condition with onset between ages 2 and 4 years, when painful circumscribed calluses develop on the pressure points of the palm of the hand and sole of the foot.[2]:512
Pathophysiology
Type II tyrosinemia is caused by a deficiency of the enzyme tyrosine aminotransferase (EC 2.6.1.5), encoded by the gene TAT. Tyrosine aminotransferase is the first in a series of five enzymes that converts tyrosine to smaller molecules, which are excreted by the kidneys or used in reactions that produce energy. This form of the disorder can affect the eyes, skin, and mental development. Symptoms often begin in early childhood and include excessive tearing, abnormal sensitivity to light (photophobia), eye pain and redness, and painful skin lesions on the palms and soles. About half of individuals with type II tyrosinemia are also mentally challenged. Type II tyrosinemia occurs in fewer than 1 in 250,000 individuals.[citation needed]
See also
References
- ↑ 1.0 1.1 James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN 0-7216-2921-0.
- ↑ Freedberg, et al. (2003). Fitzpatrick's Dermatology in General Medicine. (6th ed.). McGraw-Hill. ISBN 0-07-138076-0.
<templatestyles src="Asbox/styles.css"></templatestyles>
